Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01489904

Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy

Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial.

Sponsor: Allergan

Conditions Cerebral Palsy Sialorrhea

Interventions BOTULINUM NEUROTOXIN TYPE-A

Updated 5 times since 2017 Last updated: Oct 28, 2012 Started: Nov 30, 2011 Primary completion: Nov 30, 2011 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01489904, this PHASE2/PHASE3 trial focuses on Cerebral Palsy and Sialorrhea and remains ongoing. Sponsored by Allergan, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan
Hospital Vall d'Hebron

Data source: Hospital Vall d'Hebron

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain